Experimental drug lepodisiran lowers heart disease markers by 94%

Eli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at reducing levels of lipoprotein(a) [Lp(a)], a genetic risk factor associated with heart disease.

The ALPACA study,…